Neither company has confirmed the move and Credit Suisse analyst Vamil Divan would be surprised if it came to fruition, according to Barron's.
Divan said Soriot's background in branded pharmaceuticals doesn't mesh with Teva's generics focus. Soriot's move would also mean he'll miss out on much-anticipated data in AstraZeneca's MYSTIC immune-oncology agents, which doesn't make much sense to Credit Suisse.
But Divan said investors shouldn't rule out the move quite yet. Calcalist was first to report that Teva's previous CEO, Erez Vigodman, was leaving. Divan advised clients to look for a confirmation or denial at tomorrow's Teva shareholder meeting.
Teva stock traded up almost 4% and AstraZeneca stock fell 1.6% by Thursday's close.
What's Hot On TheStreet
How can we argue with this one: Shark Tank Star Kevin O'Leary is more fond of Tesla's (TSLA) product than its stock.
"At some point it has to fall to gravity," he said told TheStreet's Scott Gamm in an interview. "It's been trading on a different planet for years and now it has to trade on Earth." Amen.
Relax Apple stock bulls: For now, reports suggest a moderate delay in the Apple (AAPL) iPhone 8 ramp, rather than something more severe points out TheStreet's Eric Jhonsa. So far, the market has shrugged off concerns on a possible delayed iPhone 8 release (as in it misses the holiday launch window). But it's worthwhile to keep something in mind: Apple shares have lagged the S&P 500 over the past month, so some doubt may be trickling into the bull camp.